Lihong Cao

Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis

Jie Jin, Jinghan Wang, H. Tong, 2015, PloS one.

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation

Yue-min Kuang, Liya Ma, H. Tong, 2022, Frontiers in Oncology.

Case Report: Pathogenesis With a Rare RHOA A161E Mutation in a Patient With Angioimmunoblastic T-Cell Lymphoma

Jian Huang, H. Tong, J. Qin, 2022, Frontiers in Genetics.

CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study

Jiong Hu, Jie Jin, W. Qian, 2020, Cancer medicine.

The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy

Jian Huang, Jie Jin, W. Qian, 2015, Leukemia & lymphoma.

Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Jie Jin, Z. Zhuang, H. Tong, 2018, International journal of clinical and experimental pathology.

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report

H. Tong, J. Qin, J. Jin, 2023, SAGE Open Medical Case Reports.